<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23473">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02029313</url>
  </required_header>
  <id_info>
    <org_study_id>PMK-M01RS1</org_study_id>
    <nct_id>NCT02029313</nct_id>
  </id_info>
  <brief_title>Safety and the Pharmacokinetic Study of Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma</brief_title>
  <official_title>A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium) Tablet 10mg in Healthy Male Korean Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaKing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaKing</source>
  <oversight_info>
    <authority>Republic of Korea: Korea Food &amp; Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of A center, Randomized, Open label, single dose, Placebo-controlled,
      2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic
      Characteristics of MKT-N2 (Montelukast) and Singulair® (montelukast sodium) tablet 10mg in
      Healthy Male Korean Subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Number of participants with Adverse event</measure>
    <time_frame>1day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles</measure>
    <time_frame>1day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood evaluation variables: Cmax, AUCt (t=24 h), AUC∞, tmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Asthma and Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>MKT-N2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Singulair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Montelukast sodium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <arm_group_label>MKT-N2</arm_group_label>
    <arm_group_label>Singulair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast sodium</intervention_name>
    <arm_group_label>MKT-N2</arm_group_label>
    <arm_group_label>Singulair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Korean Male  over20, under 45 years old

          -  55kg over weight, IBW +-20% range male

        Exclusion Criteria:

          -  Males who have gotten a clinically significant  of liver, pancreas, kidneys, nervous
             system, respiratory system, endocrine system, blood cancer, mental illness,
             cardiovascular, urinary tract disease, or a history corresponding

          -  Males who have gotten a history of gastrointestinal disease

          -  Males who have gotten a history of hypersensitivity to montelukast or reaction to
             other drugs(aspirin, antibiotics)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Soohyun Lee</last_name>
    <phone>82-2-6925-4068</phone>
    <email>isulala@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Junggu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangheon Cho</last_name>
      <phone>82-32-890-1122</phone>
      <email>shcho123@inha.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>November 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
